FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/TGTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

TG Therapeutics Inc (TGTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

TG Therapeutics (TGTX) trades at $59.83, up 3.18% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported robust revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS results have missed expectations. Positive sentiment is driven by BRIUMVI's market share gains and buyout speculation, with the CEO targeting a $1B revenue run rate.
The outlook is positive given analyst consensus with an $80.50 price target and 84.6% buy ratings, but risks include ongoing legal scrutiny and earnings volatility. Key catalysts are subcutaneous BRIUMVI data in 2026-2027 and potential acquisition interest, though execution on guidance remains critical for sustained upside.
Read full analysis

Key Stats

  • Market Cap
    $9.16B
  • Volume
    2,304,092
  • Sector
    Health
  • 52W High
    $63.38
  • 52W Low
    $26.94
  • Typical Hold Time
    17 Days
  • Enterprise Value
    $9.36B
  • Div Yield
    -
  • Trading Activity
    66% Sell | 34% Buy
$63.3
52W Low: $26.94
12 Mar 2026
52W High: $63.38
09 Nov 2026

Track TG Therapeutics Inc (TGTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.94 and a high of $63.38, highlighting its annual price range. Buy and sell TG Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Most Recent News

Content is generated by Aura AI

Paracetamol market to surpass $15B by 2032, led by Asia-Pacific growth and rising demand for pain relief.

The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...

Market News
45 minutes ago
Mordor Intelligence
Bullish
news icon
Paracetamol market to surpass $15B by 2032, led by Asia-Pacific growth and rising demand for pain relief.

New Russian-linked cyber tool spies on NATO, EU emails via Microsoft Exchange servers

ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...

Market News
45 minutes ago
Eset Research
Bearish
news icon
New Russian-linked cyber tool spies on NATO, EU emails via Microsoft Exchange servers

Trogenix appoints John Young as Chair and Josh Murray as Non-Executive Director to boost global growth and US expansion.

Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...

Market News
3 hours ago
Na
Bullish
news icon
Trogenix appoints John Young as Chair and Josh Murray as Non-Executive Director to boost global growth and US expansion.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $9.16B
  • Volume
    2,304,092
  • Sector
    Health
  • 52W High
    $63.38
  • 52W Low
    $26.94
  • Typical Hold Time
    17 Days
  • Enterprise Value
    $9.36B
  • Div Yield
    -
  • Trading Activity
    66% Sell | 34% Buy
$63.3
52W Low: $26.94
12 Mar 2026
52W High: $63.38
09 Nov 2026

Track TG Therapeutics Inc (TGTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.94 and a high of $63.38, highlighting its annual price range. Buy and sell TG Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!